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while being very effective. Interim imaging with angiography, OCT and IVUS suggest
effective inhibition of neointimal hyperplasia with a high rate of strut coverage.
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Background: The everolimus-eluting stents, Xience TM, has shown the best safety
and efficacy profile in the trials conducted so far. Recently a new everolimus-eluting
stent with a platinum based platform has been introduced in the market, the Promus
Element TM. There is only one study comparing both stents but with important
exclusion criteria. We have conducted a randomized all comers study aimed to compare
these stents in a real practice scenario.
Methods: During a 12 months period patients undergoing revascularization and
suitable for a long-term dual antiplatelet therapy were randomized to treatment with
Xience Prime (XP) or Promus Element (PE) stents. A similar strategy of implantation
was applied (comparable implantation pressure, predilatation, postdilatation or IVUS
usage). Primary end-point is death, infarction and target lesion revascularization at 12
months.
Results: A total of 300 pts have been included, 150 treated with XP and 150 with PE.
The clinical and angiographic characteristics were well balanced in both groups without
significant differences. After a median follow up of 350 days (241-431) in the XP group
there were 4 (2.7%) deaths, 3 cardiac (2 sudden, 1 infarction), 1 (0.7%) non-lethal
infarction and 5 (3.3%) revascularizations (2 in restenosis and 3 in new lesion). There
were 2 (1.3%) thrombosis, 1 definite and 1 probable, the latter corresponding to one
of the sudden deaths. In the PE group there were 3 (2%) deaths (1 cardiac due to heart
failure), 2 (1.3%) non-lethal infarctions and 6 (4%) revascularizations (3 in restenosis
and 3 in new lesions). No thrombosis were reported. In the analysis of survival curves
no significant differences were observed for the primay end-point (7 pts in XP group
and 8 in PE group have reached this end-point so far).
Conclusion: The preliminary results of this all comers trial do not show significant
differences between Xience Prime and Promus Element stents. A longer follow-up is
required and will be reported.
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Background: Drug-eluting stents reduce the rate of TLR compared with bare metal
stents. However, there is still concern of an increased incidence of very late stent
thrombosis associated with 1st generation DES potentially related to the durable
polymer. The BioFreedom™ stent (BFD) releases Biolimus A9™, without the use of
a polymer or binder. This trial aims to demonstrate the safety and effectiveness of the
BioFreedom stent as compared to the Taxus Liberté™ stent.
Methods: The BioFreedom FIM trial is a prospective, multi-center, randomized,
single-blind study. In total, 182 patients were enrolled in two cohorts and randomized
to BFD Standard Dose (SD, 15.6 μg/mm), or BFD Low Dose (LD, 7.8 μg/mm), or
Taxus Liberté™ drug eluting stents at 4 centers in Germany. The first 75 patients
received angio and IVUS FU at 4 months (1st cohort), the remaining patients (n=107)
received angio and IVUS FU at 12 months (2nd cohort). The primary endpoint is in-
stent Late Lumen Loss (LL) at 12 months. The secondary endpoints are IVUS
neointimal volume at 4 months; MACE (death, MI, emergent Bypass or clinically-
driven TLR) and ST rates (ARC defined) at 30 days, 4 and 12 months, 2, 3, 4 and 5
years.
Results: At 12 months, the clinical FU for all patients was 99% and 92% of patients
had angiographic FU (2nd cohort). The in-stent LL was non inferior in BFD SD
vs.Taxus: 0.17mm [0.09, 0.39] vs. 0.35mm [0.22, 0.57] Pnon-inf=0.001), with a trend
towards superiority for BFD SD compared to Taxus (Psup=0.11) at 12 months. There
was no significant difference in MACE (BFD SD: 6.1% vs. BFD LD: 11.6% vs. Taxus
5.5%). No stent thrombosis was seen in either BFD SD, BFD LD or Taxus. The 2-year
clinical evaluation is ongoing and will be available at the time of this presentation.
Conclusion: The BioFreedom polymer-free drug coated stent had comparable efficacy
in inhibiting neointimal hyperplasia vs. a currently available DES with durable polymer
at 12 months in a randomized clinical trial. Both BFD SD and BFD LD demonstrated
sustained safety up to 12 months, including absence of stent thrombosis. The
BioFreedom FIM 2-year follow-up results will be reported for the 1st time during this
presentation.
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Background: Despite established clinical and procedural benefits, direct stenting (DS)
remains challenging in complex coronary lesions given the relatively bulky profile of
conventional stents. Hereby, we report our preliminary experience using the Acrobat
Svelte™ system - a novel stent mounted on a 0.014’ fixed wire system - which may
help the strategy of DS in complex coronary lesions. We thus aimed to appraise the
risk-benefit balance of the Acrobat Svelte™ in a multicenter observational study.
Methods: DS with the Acrobat Svelte™ was attempted in cases of severe vessel
tortuosity, angulated take off, severe calcification, or when other stents failed to cross
the lesion. Primary end-point of the study was device procedural success defined as
residual stenosis <30%.
Results: 34 patients (36 lesions) were enrolled. Complex features were highly
prevalent, with severe vessel tortuosity in 7 (20.6 %), angulated take off in 7 (20.6%),
severe calcification in 8 (23.5%), or prior other stent failure in 1 case (2.94%). In order
to deliver the stent, a 5Fr diagnostic catheter was used in 3 patients (9%), a 6Fr
diagnostic catheter in 1 (3%), and a 6Fr guiding catheter in the other 30 patients (88%),
whereas a buddy wire was needed in 5 patients (15%). Stent crossed the lesions at first
attempt in all cases. Mean stent size was 3.1±0.4 mm and mean stent length was
17.3±3.9 mm, with 1.2±0.44 stents per patient. Post-dilatation was mandatory in 4
patients (11.7%) to achieve procedural success. Baseline stenosis by QCA was
76.2±12.3% with mean minimal lumen diameter (MLD) of 0.71±0.36 mm. MLD post
stenting was 3.1±0.43 mm with an acute gain 2.4±0.61. Device success was achieved
in 31 patients (91.2%), with no edge dissection in any patient and a mean procedural
time of 42.2±31 minutes.
Conclusion: The Acrobat Svelte™ facilitates DS either utilizing diagnostic or guiding
catheters, and can be used to treat a wide range of coronary anatomies and lesions
drastically reducing the need of coronary guidewires and pre-dilatation balloon
catheters.
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Background: Data for long-term serial change of luminal diameter after drug-eluting
stents (DES) are limited. To evaluate these pattern of different DES, we analyzed serial
follow-up of angiographic outcomes of zotarolimus-eluting stents (ZES), sirolimus-
eluting stents (SES), and paclitaxel-eluting stents (PES) groups in the ZEST trial.
Methods: In the ZEST trial, patients were randomized to receive ZES, SES or PES in
a 1:1:1 fashion. Complete after-procedure, 9-month, and 2-year angiographic data were
available in 111 patients with 165 lesions (36, 40, and 35 patients, respectively).
Results: Baseline clinical, angiographic, and procedural characteristics were similar
among the three groups. Quantitative angiographic analysis revealed a significant
decrease in minimal luminal diameter from stent implantation to 9 months in all groups
(from 2.71 ± 0.49 mm to 2.21 ± 0.42 in ZES group, p<0.001; from 2.79 ± 0.49 mm to
2.58 ± 0.57 mm in SES group, p<0.001; from 2.66 ± 0.45 mm to 2.19 ± 0.52 mm in
PES group, p<0.001). However, significant late improvement in luminal diameter was
observed between 9 months and 2 years in all groups with different degree of luminal
change (from 2.21 ± 0.42 mm to 2.39 ± 0.58 mm in ZES group, p=0.001; from 2.58 ±
0.57 mm to 2.66 ± 0.60 mm in SES group, p=0.039; from 2.19 ± 0.52 mm to 2.43 ±
0.52 mm in PES group, p<0.001) (Figure).
Conclusion: Serial angiographic analysis for up to 2 years in the ZEST trial revealed
a biphasic luminal response characterized by an early progression phase until 9 months
and late regression phase from 9 months to 2 years with different degree after DES
implantation.
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